Aaron Gerds, MD, MS, Cleveland Clinic

Unveiling Practice-Changing Data in CLL, GVHD, and MPNs: Drs Catherine Coombs, Nelli Bejanyan, and Aaron Gerds

December 13th 2022

Dr. Gerds on the VERIFY Trial Examining Rusfertide in Polycythemia Vera

September 27th 2022

Aaron T. Gerds, MD, MS, discusses the phase 3 VERIFY trial examining rusfertide in patients with polycythemia vera.

Dr. Gerds on Emerging Agents in Myelofibrosis

January 27th 2022

Aaron T. Gerds, MD, MS, discusses emerging agents in myelofibrosis.

Dr. Gerds on the Rationale for the Real-World REVEAL Study in Polycythemia Vera

January 17th 2022

Aaron T. Gerds, MD, MS, discusses the rationale for the real-world REVEAL study in polycythemia vera.

PERSIST-1 and PERSIST-2 Trials in Myelofibrosis

September 20th 2021

Expert hematologist/oncologists review the use of pacritinib for the treatment of myelofibrosis, as seen in the PERSIST-1 and PERSIST-2 trials.

Role of JAK-STAT Pathway in Myelofibrosis

September 20th 2021

Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the impact of pathways, including JAK-STAT, on myelofibrosis disease progression and discuss considerations for the use of JAK inhibitors.

Monitoring Treatment Response in MF

September 13th 2021

Hematology/oncology experts review their approach to monitoring treatment response in myelofibrosis (MF) and when they would consider switching therapies.

Impact of Cytopenias on MF Treatment

September 13th 2021

Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the importance of allele burden in myelofibrosis (MF) and how cytopenias can limit treatment options for patients with myelofibrosis.

Challenges in Myelofibrosis Treatment

September 7th 2021

Experts in hematology/oncology comment on challenges in treating patients with myelofibrosis.

Treatment Strategies for Primary Myelofibrosis

September 7th 2021

Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review key updates to NCCN guidelines for primary myelofibrosis and discuss treatment options for the disease.

Risk Stratification and Patient Classification for PMF

August 30th 2021

Aaron Gerds, MD, MS, provides insight on determining low- vs high-risk primary myelofibrosis, the role of molecular status on treatment, and his approach toward symptom burden assessment.

Overview of Primary Myelofibrosis

August 30th 2021

Srdan Verstovsek, MD, PhD, describes the classic signs and symptoms of primary myelofibrosis (PMF), along with goals of therapy.